To watch the entire series for free please visit:
[ Ссылка ]
About this Series
Acute myeloid leukemia (AML) is largely a disease of older adults, and its incidence in the United States continues to rise as the population ages. In 2019, there were almost 21,500 new cases and approximately 10,500 deaths.
Survival for the oldest patients has improved very little in decades. Recently, however, greater understanding of the biology of AML and its cytogenetic underpinnings has led to a proliferation of new therapeutic options that may begin to improve outcomes.
For example, if the patient has mutation of FLT3, the FLT3 receptor is activated and specific inhibitors of FLT3 can be used to suppress the growth of those leukemia cells. Similarly, knowing that a patient has an inherited mutation may affect the optimal treatment plan, including choice of prospective donors for allogeneic transplant.
Hematologists/oncologists from the University of Chicago discuss the growing importance of genetic testing and screening to individualize treatment in AML patients. They examine risk assessment, factors affecting choice of therapy, and the growing range of treatment options, including allogeneic stem cell transplant in the elderly.
